For example, when DFO and the HIF-1α inhibitor YC1 were formulated into transferrin-decorated liposome nanoparticles and targeted to transferrin receptor-expressing pancreatic cancer xenografts in mice, xenograft tumor regression was observed [62]. This evidence concerns the gene TFRC and pancreatic neoplasm.